TAK-123 tested in healthy volunteers for safety
NCT ID NCT04155567
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a drug called TAK-123 in 10 healthy Japanese men to see how the body absorbs and processes it, and whether it causes any side effects. The drug was given as an infusion, and researchers measured levels of its components in the blood. Since this was a safety and pharmacokinetic study in healthy volunteers, it does not aim to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-123 (a combination of phenylacetate and benzoate)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sekino Clinical Pharmacology Clinic
Toshima-ku, Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults